Abstract
Phialophora verrucosa causes several fungal human diseases, mainly chromoblastomycosis, which is extremely difficult to treat. Several studies have shown that human immunodeficiency virus peptidase inhibitors (HIV-PIs) are attractive candidates for antifungal therapies. This work focused on studying the action of HIV-PIs on peptidase activity secreted by P. verrucosa and their effects on fungal proliferation and macrophage interaction. We detected a peptidase activity from P. verrucosa able to cleave albumin, sensitive to pepstatin A and HIV-PIs, especially lopinavir, ritonavir and amprenavir, showing for the first time that this fungus secretes aspartic-type peptidase. Furthermore, lopinavir, ritonavir and nelfinavir reduced the fungal growth, causing remarkable ultrastructural alterations. Lopinavir and ritonavir also affected the conidia-macrophage adhesion and macrophage killing. Interestingly, P. verrucosa had its growth inhibited by ritonavir combined with either itraconazole or ketoconazole. Collectively, our results support the antifungal action of HIV-PIs and their relevance as a possible alternative therapy for fungal infections.
Keywords:
Chromoblastomycosis; HIV peptidase inhibitors; antifungal activity; aspartic peptidase; cellular interaction.
MeSH terms
-
Antifungal Agents / chemical synthesis
-
Antifungal Agents / chemistry
-
Antifungal Agents / pharmacology*
-
Aspartic Acid Proteases / antagonists & inhibitors*
-
Aspartic Acid Proteases / metabolism
-
Carbamates / chemical synthesis
-
Carbamates / chemistry
-
Carbamates / pharmacology
-
Dose-Response Relationship, Drug
-
Furans
-
HIV Protease Inhibitors / chemical synthesis
-
HIV Protease Inhibitors / chemistry
-
HIV Protease Inhibitors / pharmacology*
-
Humans
-
Lopinavir / chemical synthesis
-
Lopinavir / chemistry
-
Lopinavir / pharmacology
-
Macrophages / drug effects*
-
Macrophages / metabolism
-
Microbial Sensitivity Tests
-
Molecular Structure
-
Phialophora / drug effects*
-
Phialophora / enzymology
-
Phialophora / growth & development
-
Ritonavir / chemical synthesis
-
Ritonavir / chemistry
-
Ritonavir / pharmacology
-
Structure-Activity Relationship
-
Sulfonamides / chemical synthesis
-
Sulfonamides / chemistry
-
Sulfonamides / pharmacology
Substances
-
Antifungal Agents
-
Carbamates
-
Furans
-
HIV Protease Inhibitors
-
Sulfonamides
-
Lopinavir
-
amprenavir
-
Aspartic Acid Proteases
-
Ritonavir
Grants and funding
This study was supported by grants from the Brazilian agencies: Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundação de Amparo à Pesquisa no Estado do Rio de Janeiro (FAPERJ), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES Financial code 001) and Fundação Oswaldo Cruz (FIOCRUZ).